We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
Read MoreHide Full Article
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release fourth-quarter 2022 results on Feb 28, before the opening bell.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 30.5%. It had an average negative surprise of 10.10% in the past four quarters.
Q4 Estimates
The Zacks Consensus Estimate for revenues in the fourth quarter is pegged at $934.5 million, indicating a 14.1% decline from the year-ago quarter's reported figure. The consensus mark for earnings is pegged at 32 cents per share, indicating a 57.9% decline from the prior-year quarter's reported number.
Factors to Note
DENTSPLY SIRONA’s Technologies & Equipment segment is likely to have witnessed organic growth in the fourth quarter of 2022. Higher demand for clear aligners and imaging equipment is likely to have driven the segment’s sales growth, partially offset by weakness in CAD/CAM.
Soft demand in China and the United States is likely to have hurt the Consumable segment’s sales in the fourth quarter. However, recovering demand for preventive consumables is likely to provide some cushion.
DENTSPLY SIRONA’s total revenues have been unfavorably impacted by foreign currency movement in the third quarter. The trend is likely to have continued in the fourth quarter as well.
On its third-quarter earnings call, XRAY’s management stated that it was encouraged by double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment. However, continued macroeconomic headwinds, including foreign currency impacts, global supply-chain challenges, and regional softness in China and the United States are anticipated to have offset above-mentioned growth. The company may provide updated view on macro headwinds and business performance on its fourth-quarter earnings call.
The gross margin and adjusted EPS are likely to have been adversely impacted by inflationary pressures.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (54 cents per share) and the Zacks Consensus Estimate (59 cents per share), is -8.60%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around.
Penumbra (PEN - Free Report) has an Earnings ESP of +11.11% and a Zacks Rank of 2. PEN has an estimated revenue growth rate of 19.3% for 2023.
SmileDirectClub has an Earnings ESP of +7.77% and a Zacks Rank #2 at present. SDC has an estimated earnings growth rate of 30.8% for fiscal 2023.
SmileDirectClub’s average negative earnings surprise in the trailing four quarters was 1.08%.
SiBone (SIBN - Free Report) has an Earnings ESP of +5.51% and a Zacks Rank #3 at present. SIBN has an estimated long-term growth rate of 6.3%.
SiBone’s earnings surpassed estimates in one of the trailing four quarters and lagged the same in the other three, the negative average surprise being 9.62%.
Image: Bigstock
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release fourth-quarter 2022 results on Feb 28, before the opening bell.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 30.5%. It had an average negative surprise of 10.10% in the past four quarters.
Q4 Estimates
The Zacks Consensus Estimate for revenues in the fourth quarter is pegged at $934.5 million, indicating a 14.1% decline from the year-ago quarter's reported figure. The consensus mark for earnings is pegged at 32 cents per share, indicating a 57.9% decline from the prior-year quarter's reported number.
Factors to Note
DENTSPLY SIRONA’s Technologies & Equipment segment is likely to have witnessed organic growth in the fourth quarter of 2022. Higher demand for clear aligners and imaging equipment is likely to have driven the segment’s sales growth, partially offset by weakness in CAD/CAM.
Soft demand in China and the United States is likely to have hurt the Consumable segment’s sales in the fourth quarter. However, recovering demand for preventive consumables is likely to provide some cushion.
DENTSPLY SIRONA’s total revenues have been unfavorably impacted by foreign currency movement in the third quarter. The trend is likely to have continued in the fourth quarter as well.
On its third-quarter earnings call, XRAY’s management stated that it was encouraged by double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment. However, continued macroeconomic headwinds, including foreign currency impacts, global supply-chain challenges, and regional softness in China and the United States are anticipated to have offset above-mentioned growth. The company may provide updated view on macro headwinds and business performance on its fourth-quarter earnings call.
DENTSPLY SIRONA Inc. Price and Consensus
DENTSPLY SIRONA Inc. price-consensus-chart | DENTSPLY SIRONA Inc. Quote
The gross margin and adjusted EPS are likely to have been adversely impacted by inflationary pressures.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (54 cents per share) and the Zacks Consensus Estimate (59 cents per share), is -8.60%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around.
Penumbra (PEN - Free Report) has an Earnings ESP of +11.11% and a Zacks Rank of 2. PEN has an estimated revenue growth rate of 19.3% for 2023.
Penumbra’s average earnings surprise in the trailing four quarters was 37.56%. You can see the complete list of today’s Zacks #1 Rank stocks here.
SmileDirectClub has an Earnings ESP of +7.77% and a Zacks Rank #2 at present. SDC has an estimated earnings growth rate of 30.8% for fiscal 2023.
SmileDirectClub’s average negative earnings surprise in the trailing four quarters was 1.08%.
SiBone (SIBN - Free Report) has an Earnings ESP of +5.51% and a Zacks Rank #3 at present. SIBN has an estimated long-term growth rate of 6.3%.
SiBone’s earnings surpassed estimates in one of the trailing four quarters and lagged the same in the other three, the negative average surprise being 9.62%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.